Genetics of Cardiac Developmental Disorders: Cardiomyocyte Proliferation and Growth and Relevance to Heart Failure

Annual Review of Pathology: Mechanisms of Disease

Volumn 11, Issue , 2016, Pages 395-419

  Wilsbacher, Lisa ^a   McNally, Elizabeth M ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Cardiomyopathy; Left ventricular noncompaction; Myocardial development; Noncompaction; Trabeculation

Indexed keywords

ADAMTS1 PROTEIN; BETA1 INTEGRIN; BRG1 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; FIBROBLAST GROWTH FACTOR 16; FIBROBLAST GROWTH FACTOR 20; FIBROBLAST GROWTH FACTOR 9; FIBULIN 1; FOCAL ADHESION KINASE; FOCAL ADHESION KINASE RELATED NONKINASE; HYALURONIC ACID; MYOCARDIN; NEU DIFFERENTIATION FACTOR; NEUROFIBROMIN; NOTCH1 RECEPTOR; NOTCH2 RECEPTOR; PROTEIN; PROTEIN BMP10; PROTEIN NUMB; PROTEIN NUMBLIKE; PROTEIN TBX20; RETINOID X RECEPTOR ALPHA; SOMATOMEDIN B; TRANSCRIPTION FACTOR GATA 2; TRANSCRIPTION FACTOR NKX2.5; TRANSCRIPTION FACTOR YAP1; UNCLASSIFIED DRUG; VERSICAN;

ARTICLE; CARDIAC MUSCLE; CARDIAC MUSCLE CELL; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CELL GROWTH; CELL INTERACTION; CELL PROLIFERATION; DISEASE ASSOCIATION; ENDOCARDIUM; EPICARDIUM; EPIGENETICS; EXTRACELLULAR MATRIX; GENE; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; GENETICS; HEART ARRHYTHMIA; HEART DEVELOPMENT; HEART FAILURE; HEART VENTRICLE WALL; HUMAN; JARID2 GENE; MOLECULAR BIOLOGY; MYBPC3 GENE; MYH7 GENE; NONHUMAN; POSTNATAL DEVELOPMENT; PRENATAL DEVELOPMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; SARCOMERE; TAZ GENE; THROMBOEMBOLISM; VENTRICULAR NONCOMPACTION; ABNORMALITIES; ANIMAL; DISEASE MODEL; EMBRYOLOGY; HEART VENTRICLE; PATHOLOGY; PATHOPHYSIOLOGY;

ANIMALS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; HEART FAILURE; HEART VENTRICLES; HUMANS; MYOCYTES, CARDIAC;

EID: 84971280150     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev-pathol-012615-044336     Document Type: Article

References (138)

1. Hoffman JI, Kaplan S. 2002. The incidence of congenital heart disease. J. Am. Coll. Cardiol. 39:1890-900
2. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, et al. 2006. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 113:1807-16
3. Srivastava D. 2006. Genetic regulation of cardiogenesis and congenital heart disease. Annu. Rev. Pathol. 1:199-213
4. Harvey RP. 2002. Patterning the vertebrate heart. Nat. Rev. Genet. 3:544-56
5. Van Vliet P,Wu SM, Zaffran S, Puceat M. 2012. Early cardiac development: A view from stem cells to embryos. Cardiovasc. Res. 96:352-62
6. Sylva M, van den Hoff MJ, Moorman AF. 2014. Development of the human heart. Am. J. Med. Genet. A 164A:1347-71
7. Citri A, Yarden Y. 2006. EGF-ERBB signalling: Towards the systems level. Nat. Rev. Mol. Cell Biol. 7:505-16
8. Zhao YY, Feron O, Dessy C, Han X, Marchionni MA, Kelly RA. 1999. Neuregulin signaling in the heart. Dynamic targeting of erbB4 to caveolar microdomains in cardiac myocytes. Circ. Res. 84:1380-87
9. Kang J-O, Sucov HM. 2005. Convergent proliferative response and divergent morphogenic pathways induced by epicardial and endocardial signaling in fetal heart development. Mech. Dev. 122:57-65
10. Hertig CM, Kubalak SW, Wang Y, Chien KR. 1999. Synergistic roles of neuregulin-1 and insulinlike growth factor-I in activation of the phosphatidylinositol 3-kinase pathway and cardiac chamber morphogenesis. J. Biol. Chem. 274:37362-69
11. Grego-Bessa J, Luna-Zurita L, del Monte G, Bolos V, Melgar P, et al. 2007. Notch signaling is essential for ventricular chamber development. Dev. Cell 12:415-29
12. Gassmann M, Casagranda F, Orioli D, Simon H, Lai C, et al. 1995. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature 378:390-94
13. Lee KF, Simon H, Chen H, Bates B, Hung MC, Hauser C. 1995. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378:394-98
14. Meyer D, Birchmeier C. 1995. Multiple essential functions of neuregulin in development. Nature 378:386-90
15. Kramer R, Bucay N, Kane DJ, Martin LE, Tarpley JE, Theill LE. 1996. Neuregulins with an Ig-like domain are essential for mouse myocardial and neuronal development. PNAS 93:4833-38
16. Shawber CJ, Kitajewski J. 2004. Notch function in the vasculature: insights from zebrafish, mouse and man. Bioessays 26:225-34
17. Jarriault S, Brou C, Logeat F, Schroeter EH, Kopan R, Israel A. 1995. Signalling downstream of activated mammalian Notch. Nature 377:355-58
18. Chen H, ZhangW, Sun X, YoshimotoM, Chen Z, et al. 2013. Fkbp1a controls ventricular myocardium trabeculation and compaction by regulating endocardial Notch1 activity. Development 140:1946-57
19. Shou W, Aghdasi B, Armstrong DL, Guo Q, Bao S, et al. 1998. Cardiac defects and altered ryanodine receptor function in mice lacking FKBP12. Nature 391:489-92
20. Luxán G, Casanova JC, Martínez-PovedaB,Prados B, D'Amato G, et al. 2013. Mutations in theNOTCH pathway regulator MIB1 cause left ventricular noncompaction cardiomyopathy. Nat. Med. 19:193-201
21. Shi W, Chen H, Sun J, Buckley S, Zhao J, et al. 2003. TACE is required for fetal murine cardiac development and modeling. Dev. Biol. 261:371-80
22. Yang J, Bücker S, Jungblut B, Böttger T, Cinnamon Y, et al. 2012. Inhibition of Notch2 by Numb/Numblike controls myocardial compaction in the heart. Cardiovasc. Res. 96:276-85
23. McCright B, Gao X, Shen L, Lozier J, Lan Y, et al. 2001. Defects in development of the kidney, heart and eye vasculature inmice homozygous for a hypomorphic Notch2 mutation. Development 128:491-502
24. Huang J, Elicker J, Bowens N, Liu X, Cheng L, et al. 2012. Myocardin regulates BMP10 expression and is required for heart development. J. Clin. Investig. 122:3678-91
25. GalfréE, Pitt SJ, VenturiE, SitsapesanM,Zaccai NR, et al. 2012. FKBP12 activates the cardiac ryanodine receptor Ca2+-release channel and is antagonised by FKBP12.6. PLOS ONE 7:e31956
26. Pashmforoush M, Lu JT, Chen H, Amand TS, Kondo R, et al. 2004. Nkx2-5 pathways and congenital heart disease; loss of ventricular myocyte lineage specification leads to progressive cardiomyopathy and complete heart block. Cell 117:373-86
27. Chen H, Shi S, Acosta L, Li W, Lu J, et al. 2004. BMP10 is essential for maintaining cardiac growth during murine cardiogenesis. Development 131:2219-31
28. ZhangW, Chen H,Wang Y, YongW, Zhu W, et al. 2011. Tbx20 transcription factor is a downstream mediator for bone morphogenetic protein-10 in regulating cardiac ventricular wall development and function. J. Biol. Chem. 286:36820-29
29. Shen T, Aneas I, Sakabe N, Dirschinger RJ, Wang G, et al. 2011. Tbx20 regulates a genetic program essential to adult mouse cardiomyocyte function. J. Clin. Investig. 121:4640-54
30. Kraus F, Haenig B, Kispert A. 2001. Cloning and expression analysis of the mouse T-box gene Tbx20. Mech. Dev. 100:87-91
31. Kirk EP, Sunde M, Costa MW, Rankin SA, Wolstein O, et al. 2007. Mutations in cardiac T-box factor gene TBX20 are associated with diverse cardiac pathologies, including defects of septation and valvulogenesis and cardiomyopathy. Am. J. Hum. Genet. 81:280-91
32. Cai CL, Zhou W, Yang L, Bu L, Qyang Y, et al. 2005. T-box genes coordinate regional rates of proliferation and regional specification during cardiogenesis. Development 132:2475-87
33. Gitler AD, Zhu Y, Ismat FA, Lu MM, Yamauchi Y, et al. 2003. Nf1 has an essential role in endothelial cells. Nat. Genet. 33:75-79
34. Brannan CI, Perkins AS, Vogel KS, Ratner N, Nordlund ML, et al. 1994. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crestderived tissues. Genes Dev. 8:1019-29
35. Suri C, Jones PF, Patan S, Bartunkova S,Maisonpierre PC, et al. 1996. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87:1171-80
36. JeanssonM, Gawlik A, Anderson G, Li C, Kerjaschki D, et al. 2011. Angiopoietin-1 is essential in mouse vasculature during development and in response to injury. J. Clin. Investig. 121:2278-89
37. Dumont DJ, Gradwohl G, Fong GH, PuriMC, Gertsenstein M, et al. 1994. Dominant-negative and targeted nullmutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev. 8:1897-909
38. Ferrara N, Gerber HP, LeCouter J. 2003. The biology of VEGF and its receptors. Nat. Med. 9:669-76
39. Ferrara N, Carver-Moore K, ChenH,DowdM, Lu L,O'Shea KS, et al. 1996. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380:439-42
40. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, et al. 1996. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380:435-39
41. Miquerol L, Langille BL, Nagy A. 2000. Embryonic development is disrupted by modest increases in vascular endothelial growth factor gene expression. Development 127:3941-46
42. Hallaq H, Pinter E, Enciso J,McGrath J, ZeissC, et al. 2004. A nullmutation ofHhex results in abnormal cardiac development, defective vasculogenesis and elevated Vegfa levels. Development 131:5197-209
43. Mass E, Wachten D, Aschenbrenner AC, Voelzmann A,HochM. 2014. Murine Creld1 controls cardiac development through activation of calcineurin/NFATc1 signaling. Dev. Cell 28:711-26
44. Jenkins SJ, Hutson DR, Kubalak SW. 2005. Analysis of the proepicardium-epicardium transition during the malformation of the RXRα-/- epicardium. Dev. Dyn. 233:1091-101
45. Pennisi DJ, Ballard VLT, Mikawa T. 2003. Epicardium is required for the full rate of myocyte proliferation and levels of expression of myocyte mitogenic factors FGF2 and its receptor, FGFR-1, but not for transmural myocardial patterning in the embryonic chick heart. Dev. Dyn. 228:161-72
46. Kwee L, Baldwin HS, Shen HM, Stewart CL, Buck C, et al. 1995. Defective development of the embryonic and extraembryonic circulatory systems in vascular cell adhesion molecule (VCAM-1) deficient mice. Development 121:489-503
47. Germain P, Chambon P, Eichele G, Evans RM, Lazar MA, et al. 2006. International Union of Pharmacology. LXIII. Retinoid X receptors. Pharmacol. Rev. 58:760-72
48. Kastner P, Grondona JM, Mark M, Gansmuller A, LeMeurM, et al. 1994. Genetic analysis of RXRαdevelopmental function: convergence ofRXRandRAR signaling pathways in heart and eye morphogenesis. Cell 78:987-1003
49. Sucov HM, Dyson E, Gumeringer CL, Price J, Chien KR, Evans RM. 1994. RXRα mutant mice establish a genetic basis for vitamin A signaling in heart morphogenesis. Genes Dev. 8:1007-18
50. Mendelsohn C, Lohnes D, Decimo D, Lufkin T, LeMeur M, et al. 1994. Function of the retinoic acid receptors (RARs) during development (II). Multiple abnormalities at various stages of organogenesis in RAR double mutants. Development 120:2749-71
51. Kastner P, Messaddeq N, Mark M, Wendling O, Grondona JM, et al. 1997. Vitamin A deficiency and mutations of RXRα, RXRβ and RARα lead to early differentiation of embryonic ventricular cardiomyocytes. Development 124:4749-58
52. Stuckmann I, Evans S, Lassar AB. 2003. Erythropoietin and retinoic acid, secreted from the epicardium, are required for cardiac myocyte proliferation. Dev. Biol. 255:334-49
53. Brade T, Kumar S, Cunningham TJ, Chatzi C, Zhao X, et al. 2011. Retinoic acid stimulates myocardial expansion by induction of hepatic erythropoietin which activates epicardial Igf2. Development 138:139-48
54. Merki E, Zamora M, Raya A, Kawakami Y, Wang J, et al. 2005. Epicardial retinoid X receptor α is required for myocardial growth and coronary artery formation. PNAS 102:18455-60
55. Ackerman KG, Greer JJ. 2007. Development of the diaphragm and genetic mouse models of diaphragmatic defects. Am. J. Med. Genet. C Semin. Med. Genet. 145C:109-16
56. Wu H, Lee SH, Gao J, Liu X, Iruela-Arispe ML. 1999. Inactivation of erythropoietin leads to defects in cardiac morphogenesis. Development 126:3597-605
57. Li P, Cavallero S, Gu Y, Chen THP, Hughes J, et al. 2011. IGF signaling directs ventricular cardiomyocyte proliferation during embryonic heart development. Development 138:1795-805
58. Lavine KJ, Yu K, White AC, Zhang X, Smith C, et al. 2005. Endocardial and epicardial derived FGF signals regulate myocardial proliferation and differentiation in vivo. Dev. Cell 8:85-95
59. Lu SY, Sheikh F, Sheppard PC, Fresnoza A, Duckworth ML, et al. 2008. FGF-16 is required for embryonic heart development. Biochem. Biophys. Res. Commun. 373:270-74
60. Hotta Y, Sasaki S, KonishiM, Kinoshita H, Kuwahara K, et al. 2008. Fgf16 is required for cardiomyocyte proliferation in the mouse embryonic heart. Dev. Dyn. 237:2947-54
61. Hayashi T, Ray CA, Bermingham-McDonogh O. 2008. Fgf20 is required for sensory epithelial specification in the developing cochlea. J. Neurosci. 28:5991-99
62. Kern CB, TwalWO, Mjaatvedt CH, Fairey SE, Toole BP, et al. 2006. Proteolytic cleavage of versican during cardiac cushion morphogenesis. Dev. Dyn. 235:2238-47
63. Yamamura H, Zhang M, Markwald RR, Mjaatvedt CH. 1997. A heart segmental defect in the anteriorposterior axis of a transgenic mutant mouse. Dev. Biol. 186:58-72
64. Mjaatvedt CH, Yamamura H, Capehart AA, Turner D, Markwald RR. 1998. The Cspg2 gene, disrupted in the hdf mutant, is required for right cardiac chamber and endocardial cushion formation. Dev. Biol. 202:56-66
65. Camenisch TD, Spicer AP, Brehm-Gibson T, Biesterfeldt J, Augustine ML, et al. 2000. Disruption of hyaluronan synthase-2 abrogates normal cardiac morphogenesis and hyaluronan-mediated transformation of epithelium to mesenchyme. J. Clin. Investig. 106:349-60
66. Cooley MA, Fresco VM, Dorlon ME, Twal WO, Lee NV, et al. 2012. Fibulin-1 is required during cardiac ventricular morphogenesis for versican cleavage, suppression of ErbB2 and Erk1/2 activation, and to attenuate trabecular cardiomyocyte proliferation. Dev. Dyn. 241:303-14
67. Stankunas K,Hang CT, Tsun ZY, Chen H, LeeNV, et al. 2008. Endocardial Brg1 represses ADAMTS1 to maintain the microenvironment for myocardial morphogenesis. Dev. Cell 14:298-311
68. Takada Y, Ye X, Simon S. 2007. The integrins. Genome Biol. 8:215
69. Ieda M, TsuchihashiT, IveyKN,RossRS,HongT-T, et al. 2009. Cardiac fibroblasts regulatemyocardial proliferation through β1 integrin signaling. Dev. Cell 16:233-44
70. DiMichele LA, Hakim ZS, Sayers RL, Rojas M, Schwartz RJ, et al. 2009. Transient expression of FRNK reveals stage-specific requirement for focal adhesion kinase activity in cardiac growth. Circ. Res. 104:1201-8
71. Peng X, Wu X, Druso JE, Wei H, Park AY-J, et al. 2008. Cardiac developmental defects and eccentric right ventricular hypertrophy in cardiomyocyte focal adhesion kinase (FAK) conditional knockout mice. PNAS 105:6638-43
72. Zhao B, Li L, LeiQ,Guan KL. 2010. TheHippo-YAP pathway in organ size control and tumorigenesis: An updated version. Genes Dev. 24:862-74
73. von Gise A, Lin Z, Schlegelmilch K, Honor LB, Pan GM, et al. 2012. YAP1, the nuclear target of Hippo signaling, stimulates heart growth through cardiomyocyte proliferation but not hypertrophy. PNAS 109:2394-99
74. Reamon-Buettner SM, Borlak J. 2010. NKX2-5: an update on this hypermutable homeodomain protein and its role in human congenital heart disease (CHD). Hum. Mutat. 31:1185-94
75. Ashraf H, Pradhan L, Chang EI, Terada R, Ryan NJ, et al. 2014. A mouse model of human congenital heart disease: high incidence of diverse cardiac anomalies and ventricular noncompaction produced by heterozygous Nkx2-5 homeodomain missense mutation. Circ. Cardiovasc. Genet. 7:423-33
76. Ouyang P, Saarel E, Bai Y, Luo C, Lv Q, et al. 2011. A de novo mutation in NKX2.5 associated with atrial septal defects, ventricular noncompaction, syncope and sudden death. Clin. Chim. Acta 412:170-75
77. Tevosian SG, Deconinck AE, Tanaka M, Schinke M, Litovsky SH, et al. 2000. FOG-2, a cofactor for GATA transcription factors, is essential for heart morphogenesis and development of coronary vessels from epicardium. Cell 101:729-39
78. Svensson EC, Huggins GS, Lin H, Clendenin C, Jiang F, et al. 2000. A syndrome of tricuspid atresia in mice with a targeted mutation of the gene encoding Fog-2. Nat. Genet. 25:353-56
79. Zhou B, Ma Q, Kong SW, Hu Y, Campbell PH, et al. 2009. Fog2 is critical for cardiac function and maintenance of coronary vasculature in the adult mouse heart. J. Clin. Investig. 119:1462-76
80. Garnatz AS, Gao Z, Broman M, Martens S, Earley JU, Svensson EC. 2014. FOG-2 mediated recruitment of the NuRD complex regulates cardiomyocyte proliferation during heart development. Dev. Biol. 395:50-61
81. Healy S, Khan DH, Davie JR. 2011. Gene expression regulation through 14-3-3 interactions with histones and HDACs. Discov. Med. 11:349-58
82. Kosaka Y, Cieslik KA, Li L, Lezin G, Maguire CT, et al. 2012. 14-3-3ϵplays a role in cardiac ventricular compaction by regulating the cardiomyocyte cell cycle. Mol. Cell. Biol. 32:5089-102
83. Wang B, Weidenfeld J, Lu MM, Maika S, KuzielWA, et al. 2004. Foxp1 regulates cardiac outflow tract, endocardial cushionmorphogenesis andmyocyte proliferation and maturation. Development 131:4477-87
84. Habas R, Kato Y, He X. 2001. Wnt/Frizzled activation of Rho regulates vertebrate gastrulation and requires a novel Formin homology protein Daam1. Cell 107:843-54
85. Li D, Hallett MA, Zhu W, Rubart M, Liu Y, et al. 2010. Dishevelled-associated activator of morphogenesis 1 (Daam1) is required for heart morphogenesis. Development 138:303-15
86. Mesaeli N, Nakamura K, Zvaritch E, Dickie P, Dziak E, et al. 1999. Calreticulin is essential for cardiac development. J. Cell Biol. 144:857-68
87. Caron KM, Smithies O. 2001. Extreme hydrops fetalis and cardiovascular abnormalities in mice lacking a functional Adrenomedullin gene. PNAS 98:615-19
88. Dackor RT, Fritz-Six K, Dunworth WP, Gibbons CL, Smithies O, Caron KM. 2006. Hydrops fetalis, cardiovascular defects, and embryonic lethality inmice lacking the calcitonin receptor-like receptor gene. Mol. Cell. Biol. 26:2511-18
89. Klein KR, KarpinichNO,Espenschied ST,WillcocksonHH,DunworthWP,et al. 2014. Decoy receptor CXCR7 modulates adrenomedullin-mediated cardiac and lymphatic vascular development. Dev. Cell 30:528-40
90. Dawson DK, Maceira AM, Raj VJ, Graham C, Pennell DJ, Kilner PJ. 2011. Regional thicknesses and thickening of compacted and trabeculated myocardial layers of the normal left ventricle studied by cardiovascular magnetic resonance. Circ. Cardiovasc. Imaging 4:139-46
91. Tizon-Marcos H, de la Paz Ricapito M, Pibarot P, Bertrand O, Bibeau K, et al. 2014. Characteristics of trabeculated myocardium burden in young and apparently healthy adults. Am. J. Cardiol. 114:1094-99
92. Sasse-Klaassen S, Gerull B, Oechslin E, Jenni R, Thierfelder L. 2003. Isolated noncompaction of the left ventricular myocardium in the adult is an autosomal dominant disorder in the majority of patients. Am. J. Med. Genet. A 119A:162-67
93. Caliskan K, Michels M, Geleijnse ML, van Domburg RT, van der Boon R, et al. 2012. Frequency of asymptomatic disease among family members with noncompaction cardiomyopathy. Am. J. Cardiol. 110:1512-17
94. Puckelwartz MJ, McNally EM. 2014. Genetic profiling for risk reduction in human cardiovascular disease. Genes (Basel) 5:214-34
95. Golbus JR, Puckelwartz MJ, Dellefave-Castillo L, Fahrenbach JP, Nelakuditi V, et al. 2014. Targeted analysis of whole genome sequence data to diagnose genetic cardiomyopathy. Circ. Cardiovasc. Genet. 7:751-59
96. Zaidi S, ChoiM,WakimotoH,Ma L, Jiang J, et al. 2013. De novo mutations in histone-modifying genes in congenital heart disease. Nature 498:220-23
97. Hoedemaekers YM, Caliskan K, Majoor-Krakauer D, van de Laar I, Michels M, et al. 2007. Cardiac β-myosin heavy chain defects in two families with non-compaction cardiomyopathy: linking noncompaction to hypertrophic, restrictive, and dilated cardiomyopathies. Eur. Heart J. 28:2732-37
98. Budde BS, Binner P, Waldmuller S, Hohne W, Blankenfeldt W, et al. 2007. Noncompaction of the ventricular myocardium is associated with a de novo mutation in the β-myosin heavy chain gene. PLOS ONE 2:e1362
99. Klaassen S, Probst S, Oechslin E, Gerull B, Krings G, et al. 2008. Mutations in sarcomere protein genes in left ventricular noncompaction. Circulation 117:2893-901
100. Dellefave LM, Pytel P, Mewborn S, Mora B, Guris DL, et al. 2009. Sarcomere mutations in cardiomyopathy with left ventricular hypertrabeculation. Circ. Cardiovasc. Genet. 2:442-49
101. Basu R, Hazra S, ShanksM, Paterson DI, Oudit GY. 2014. Novel mutation in exon 14 of the sarcomere geneMYH7in familial left ventricular noncompactionwith bicuspid aortic valve. Circ.Heart Fail. 7:1059-62
102. Finsterer J, Stollberger C, Brandau O, Laccone F, Bichler K, Laing NG. 2014. Novel MYH7 mutation associated with mild myopathy but life-threatening ventricular arrhythmias and noncompaction. Int. J. Cardiol. 173:532-35
103. Hirono K, Hata Y, Ibuki K, Yoshimura N. 2014. Familial Ebstein's anomaly, left ventricular noncompaction, and ventricular septal defect associated with an MYH7 mutation. J. Thorac. Cardiovasc. Surg. 148:e223-26
104. Nomura Y, Momoi N, Hirono K, Hata Y, Takasaki A, et al. 2015. A novel MYH7 gene mutation in a fetus with left ventricular noncompaction. Can. J. Cardiol. 31:103 e1-3
105. Yang J, ZhuM,Wang Y, Hou X, Wu H, et al. 2015. Whole-exome sequencing identify a new mutation of MYH7 in a Chinese family with left ventricular noncompaction. Gene 558:138-42
106. Arad M, Penas-Lado M, Monserrat L, Maron BJ, Sherrid M, et al. 2005. Gene mutations in apical hypertrophic cardiomyopathy. Circulation 112:2805-11
107. Stelzer JE, Dunning SB, Moss RL. 2006. Ablation of cardiac myosin-binding protein-C accelerates stretch activation in murine skinned myocardium. Circ. Res. 98:1212-18
108. Probst S,Oechslin E, Schuler P,Greutmann M, Boye P, et al. 2011. Sarcomere genemutations in isolated left ventricular noncompaction cardiomyopathy do not predict clinical phenotype. Circ. Cardiovasc. Genet. 4:367-74
109. Schaefer E, Helms P,Marcellin L, Desprez P, Billaud P, et al. 2014. Next-generation sequencing (NGS) as a fast molecular diagnosis tool for left ventricular noncompaction in an infant with compound mutations in the MYBPC3 gene. Eur. J. Med. Genet. 57:129-32
110. Wessels MW, Herkert JC, Frohn-Mulder IM, Dalinghaus M, van denWijngaard A, et al. 2014. Compound heterozygous or homozygous truncating MYBPC3 mutations cause lethal cardiomyopathy with features of noncompaction and septal defects. Eur. J. Hum. Genet. 23:922-28
111. Zahka K, Kalidas K, Simpson MA, Cross H, Keller BB, et al. 2008. Homozygous mutation of MYBPC3 associated with severe infantile hypertrophic cardiomyopathy at high frequency among the Amish. Heart 94:1326-30
112. McConnell BK, Jones KA, Fatkin D, Arroyo LH, Lee RT, et al. 1999. Dilated cardiomyopathy in homozygous myosin-binding protein-C mutant mice. J. Clin. Investig. 104:1235-44
113. Monserrat L, Hermida-Prieto M, Fernandez X, Rodriguez I, Dumont C, et al. 2007. Mutation in the alpha-cardiac actin gene associated with apical hypertrophic cardiomyopathy, left ventricular noncompaction, and septal defects. Eur. Heart J. 28:1953-61
114. Luedde M, Ehlermann P, Weichenhan D, Will R, Zeller R, et al. 2010. Severe familial left ventricular non-compaction cardiomyopathy due to a novel troponin T (TNNT2)mutation. Cardiovasc. Res. 86:452-60
115. Bagnall RD, Molloy LK, Kalman JM, Semsarian C. 2014. Exome sequencing identifies a mutation in the ACTN2 gene in a family with idiopathic ventricular fibrillation, left ventricular noncompaction, and sudden death. BMC Med. Genet. 15:99
116. Mogensen J, Murphy RT, Shaw T, Bahl A, Redwood C, et al. 2004. Severe disease expression of cardiac troponin C and T mutations in patients with idiopathic dilated cardiomyopathy. J. Am. Coll. Cardiol. 44:2033-40
117. Liu Z, LiW,Ma X, Ding N, Spallotta F, et al. 2014. Essential role of the zinc finger transcription factor Casz1 for mammalian cardiac morphogenesis and development. J. Biol. Chem. 289:29801-16
118. Xi Y, Ai T, De Lange E, Li Z,WuG, et al. 2012. Loss of function of hNav1.5 by a ZASP1 mutation associated with intraventricular conduction disturbances in left ventricular noncompaction. Circ. Arrhythm. Electrophysiol. 5:1017-26
119. Vatta M, Mohapatra B, Jimenez S, Sanchez X, Faulkner G, et al. 2003. Mutations in Cypher/ZASP in patients with dilated cardiomyopathy and left ventricular non-compaction. J. Am. Coll. Cardiol. 42:2014-27
120. Zhou Q, Chu PH, Huang C, Cheng CF, Martone ME, et al. 2001. Ablation of Cypher, a PDZ-LIM domain Z-line protein, causes a severe form of congenital myopathy. J. Cell Biol. 155:605-12
121. Ichida F, Tsubata S, Bowles KR, Haneda N, Uese K, et al. 2001. Novel gene mutations in patients with left ventricular noncompaction or Barth syndrome. Circulation 103:1256-63
122. Kenton AB, Sanchez X, Coveler KJ, Makar KA, Jimenez S, et al. 2004. Isolated left ventricular noncompaction is rarely caused by mutations in G4.5, alpha-dystrobrevin and FK Binding Protein-12. Mol. Genet. Metab. 82:162-66
123. Phoon CK, Acehan D, SchlameM, Stokes DL, Edelman-Novemsky I, et al. 2012. Tafazzin knockdown in mice leads to a developmental cardiomyopathy with early diastolic dysfunction preceding myocardial noncompaction. J. Am. Heart Assoc. 1: e000455
124. Milano A, Vermeer AM, Lodder EM, Barc J, Verkerk AO, et al. 2014. HCN4 mutations in multiple families with bradycardia and left ventricular noncompaction cardiomyopathy. J. Am. Coll. Cardiol. 64:745-56
125. Schweizer PA, Schroter J, Greiner S, Haas J, Yampolsky P, et al. 2014. The symptom complex of familial sinus node dysfunction and myocardial noncompaction is associated with mutations in theHCN4 channel. J. Am. Coll. Cardiol. 64:757-67
126. Carboni N, Politano L, Floris M, Mateddu A, Solla E, et al. 2013. Overlapping syndromes in laminopathies: A meta-analysis of the reported literature. Acta Myol. 32:7-17
127. Bonne G, Quijano-Roy S. 2013. Emery-Dreifuss muscular dystrophy, laminopathies, and other nuclear envelopathies. Handb. Clin. Neurol. 113:1367-76
128. Mewborn SK, Puckelwartz MJ, Abuisneineh F, Fahrenbach JP, Zhang Y, et al. 2010. Altered chromosomal positioning, compaction, and gene expression with a lamin A/C gene mutation. PLOS ONE 5:e14342
129. Hermida-Prieto M, Monserrat L, Castro-Beiras A, Laredo R, Soler R, et al. 2004. Familial dilated cardiomyopathy and isolated left ventricular noncompaction associated with lamin A/C gene mutations. Am. J. Cardiol. 94:50-54
130. van Berlo JH, de Voogt WG, van der Kooi AJ, van Tintelen JP, Bonne G, et al. 2005. Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: Do lamin A/C mutations portend a high risk of sudden death? J. Mol. Med. (Berl.) 83:79-83
131. Abecasis GR, Altshuler D, Auton A, Brooks LD, Durbin RM, et al. 2010. A map of human genome variation from population-scale sequencing. Nature 467:1061-73
132. Tennessen JA, Bigham AW, O'Connor TD, Fu W, Kenny EE, et al. 2012. Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science 337:64-69
133. ChangCP, Bruneau BG. 2012. Epigenetics and cardiovascular development. Annu. Rev. Physiol. 74:41-68
134. Shirato H, Ogawa S, Nakajima K, InagawaM, KojimaM, et al. 2009. A jumonji ( Jarid2) protein complex represses cyclin D1 expression by methylation of histone H3-K9. J. Biol. Chem. 284:733-39
135. Lee Y, Song AJ, Baker R, Micales B, Conway SJ, Lyons GE. 2000. Jumonji, a nuclear protein that is necessary for normal heart development. Circ. Res. 86:932-38
136. Toyoda M, Shirato H, Nakajima K, Kojima M, TakahashiM, et al. 2003. jumonji downregulates cardiac cell proliferation by repressing cyclin D1 expression. Dev. Cell 5:85-97
137. Mysliwiec MR, Bresnick EH, Lee Y. 2011. Endothelial Jarid2/Jumonji is required for normal cardiac development and proper Notch1 expression. J. Biol. Chem. 286:17193-204
138. Wang X, Haswell JR, Roberts CW. 2014. Molecular pathways: SWI/SNF (BAF) complexes are frequently mutated in cancer-mechanisms and potential therapeutic insights. Clin. Cancer Res. 20:21-27